Gibson Dunn Advised Nextech Ventures and EQT Life Sciences in $183 Million Series C Financing for Electra Therapeutics
As co-lead investors in a $183 million Series C financing for Electra Therapeutics, a clinical stage biotechnology business developing treatments against novel targets for cancer and immunological illnesses, Gibson Dunn advised Nextech Ventures and EQT Life Sciences.